Literature DB >> 8872516

Determination of bradykinin-(1-5) in inflammatory exudate by a new ELISA as a reliable indicator of bradykinin generation.

M Majima1, K Nishiyama, Y Iguchi, K Yao, M Ogino, T Ohno, N Sunahara, K Katoh, N Tatemichi, Y Takei, M Katori.   

Abstract

We have developed an ELISA for BK-(1-5) (Arg1-Pro2-Pro3-Gly4-Phe5). In rat carrageenin-induced pleurisy, in which a plasma exudation peak was observed 5 h after carrageenin, BK levels in the exudates were negligible (< 60 pg/rat). BK-(1-7) (des-Phe8-Arg9-BK) was detectable (900-400 pg/rat) over the entire course of the inflammation. However, a larger amount of BK-(1-5) was detectable in association with the increase in plasma exudation, showing a peak (8800 +/- 1200 pg/rat) 3 h after carrageenin. Bromelain (10 mg/kg, i.v.) and soy bean trypsin inhibitor (0.3 mg/rat, intra-pleural) significantly reduced BK-(1-5) levels (by 60-93%, 3, 7 and 19 h after carrageenin) and plasma exudation rates (by 61-74%, 3 and 7 h after carrageenin). Dexamethasone (0.3 mg/kg, i.p.) reduced BK-(1-5) levels (by 78%) and decreased plasma exudation (by 70%) 3 h after carrageenin. In nasal allergy patients, antigen challenge of nasal mucosa elevated BK-(1-5) levels and active kallikrein levels in nasal washes. These results verify that BK-(1-5) determined by ELISA is a good indicator for release of kinins in vivo.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8872516     DOI: 10.1007/bf02252938

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  20 in total

1.  Modulation of plasma exudation by PGE2 and that of leukocyte migration by LTB4 in inflammatory models.

Authors:  M Katori; Y Harada; A Ueno; M Majima; T Oda; M Kawamura
Journal:  Dermatologica       Date:  1989

2.  AN IN VIVO ESTIMATION OF THE POTENCIES AND HALF-LIVES OF SYNTHETIC BRADYKININ AND KALLIDIN.

Authors:  D A MCCARTHY; D E POTTER; E D NICOLAIDES
Journal:  J Pharmacol Exp Ther       Date:  1965-04       Impact factor: 4.030

3.  A significant role of plasma kallikrein-kinin system in plasma exudation of rat carrageenin-induced pleurisy.

Authors:  M Katori; M Majima; Y Harada; A Ueno
Journal:  Adv Exp Med Biol       Date:  1989       Impact factor: 2.622

4.  A radioimmunoassay for bradykinin based on monoclonal antibodies.

Authors:  E Phillips; M Webb
Journal:  J Neuroimmunol       Date:  1989-08       Impact factor: 3.478

5.  Suppression of rat deoxycorticosterone-salt hypertension by kallikrein-kinin system.

Authors:  M Majima; M Katori; M Hanazuka; S Mizogami; T Nakano; Y Nakao; R Mikami; H Uryu; R Okamura; S S Mohsin
Journal:  Hypertension       Date:  1991-06       Impact factor: 10.190

6.  Diuretic and natriuretic effect of ebelactone B in anesthetized rats by inhibition of a urinary carboxypeptidase Y-like kininase.

Authors:  M Majima; Y Kuribayashi; Y Ikeda; K Adachi; H Kato; M Katori; T Aoyagi
Journal:  Jpn J Pharmacol       Date:  1994-05

7.  A stable metabolite, Arg-Pro-Pro-Gly-Phe, of bradykinin in the degradation pathway in human plasma.

Authors:  C Shima; M Majima; M Katori
Journal:  Jpn J Pharmacol       Date:  1992-10

8.  Role of vasopressin in regulation of renal kinin excretion in Long-Evans and diabetes insipidus rats.

Authors:  M L Kauker; J T Crofton; L Share; A Nasjletti
Journal:  J Clin Invest       Date:  1984-03       Impact factor: 14.808

9.  Activation of plasma kallikrein-kinin system and its significant role in pleural fluid accumulation of rat carrageenin-induced pleurisy.

Authors:  Y Uchida; K Tanaka; Y Harada; A Ueno; M Katori
Journal:  Inflammation       Date:  1983-06       Impact factor: 4.092

10.  Oxytocin-induced natriuresis mediated by the renal kallikrein-kinin system in anesthetized male rats.

Authors:  K Adachi; M Majima; M Katori; M Nishijima
Journal:  Jpn J Pharmacol       Date:  1995-03
View more
  8 in total

1.  Blockade of bradykinin B(2) receptor suppresses acute pancreatitis induced by obstruction of the pancreaticobiliary duct in rats.

Authors:  Mitsuhiro Hirata; Izumi Hayashi; Kuniko Yoshimura; Ken-ichiro Ishii; Kazui Soma; Takashi Ohwada; Akira Kakita; Masataka Majima
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

Review 2.  The kinin system in hypertensive pathophysiology.

Authors:  Jagdish N Sharma
Journal:  Inflammopharmacology       Date:  2012-04-17       Impact factor: 4.473

3.  In vivo transfer of antisense oligonucleotide against urinary kininase blunts deoxycorticosterone acetate-salt hypertension in rats.

Authors:  I Hayashi; M Majima; T Fujita; T Okumura; Y Kumagai; N Tomita; R Morishita; J Higaki; T Ogiwara
Journal:  Br J Pharmacol       Date:  2000-10       Impact factor: 8.739

4.  Bromelain treatment decreases secretion of pro-inflammatory cytokines and chemokines by colon biopsies in vitro.

Authors:  Jane E Onken; Paula K Greer; Brian Calingaert; Laura P Hale
Journal:  Clin Immunol       Date:  2007-12-21       Impact factor: 3.969

5.  Bromelain treatment decreases neutrophil migration to sites of inflammation.

Authors:  David J Fitzhugh; Siqing Shan; Mark W Dewhirst; Laura P Hale
Journal:  Clin Immunol       Date:  2008-05-14       Impact factor: 3.969

6.  Bradykinin inhibits development of myocardial infarction through B2 receptor signalling by increment of regional blood flow around the ischaemic lesions in rats.

Authors:  Hiroshi Ito; Izumi Hayashi; Tohru Izumi; Masataka Majima
Journal:  Br J Pharmacol       Date:  2003-01       Impact factor: 8.739

7.  Plant proteolytic enzyme papain abrogates angiogenic activation of human umbilical vein endothelial cells (HUVEC) in vitro.

Authors:  Thomas Mohr; Lucia Desser
Journal:  BMC Complement Altern Med       Date:  2013-09-21       Impact factor: 3.659

8.  Enhancement of the Anti-inflammatory Effect of Bromelain by Its Immobilization on Probiotic Spore of Bacillus cereus.

Authors:  Chika Jude Ugwuodo; Tochukwu Nwamaka T Nwagu; Tochukwu Thaddeus Ugwu; Chukwudi Ogbonnaya Onwosi
Journal:  Probiotics Antimicrob Proteins       Date:  2020-11-06       Impact factor: 4.609

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.